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Abstract: The prevalence of obesity has increased worldwide, and approximately 25%–35% 
of the adult population is obese in some countries. The excess of body fat is associated with 
adverse health consequences. Considering the limited efficacy of diet and exercise in the cur-
rent obese population and the use of bariatric surgery only for morbid obesity, it appears that 
drug therapy is the only available method to address the problem on a large scale. Currently, 
pharmacological obesity treatment options are limited. However, new antiobesity drugs acting 
through central nervous system pathways or the peripheral adiposity signals and gastrointes-
tinal tract are under clinical development. One of the most promising approaches is the use of 
peptides that influence the peripheral satiety signals and brain–gut axis such as GLP-1 analogs. 
However, considering that any antiobesity drug may affect one or several of the systems that 
control food intake and energy expenditure, it is unlikely that a single pharmacological agent 
will be effective as a striking obesity treatment. Thus, future strategies to treat obesity will need 
to be directed at sustainable weight loss to ensure maximal safety. This strategy will probably 
require the coadministration of medications that act through different mechanisms.
Keywords: obesity, energy balance, pharmacotherapy
Introduction
Obesity was defined as an epidemic of the 21st century by the World Health 
Organization (WHO) and has become a serious health problem worldwide. It has been 
estimated that at least 3.4 million people die each year as a result of being overweight 
or obese and 35.8 million (2.3%) of global Disability Adjusted Life Years (DALYs) 
are caused by this pathology.1 DALY is a health gap measure that extends the concept 
of potential years of life lost due to premature death to include equivalent years of 
“healthy” life lost by virtue of being in states of poor health or disability.1
The worldwide prevalence of obesity nearly doubled between 1980 and 2008, 
and it currently affects approximately 30%–35% of the general population in the 
USA and 25% in the UK.2,3 Moreover, childhood obesity is currently one of the most 
serious health challenges, and its prevalence has increased worldwide at an alarming 
rate in recent decades.4,5 In 2012, more than 40 million children under the age of five 
were overweight or obese. Additionally, 70 million children under age five will be 
overweight or obese by 2025 if current trends continue. The WHO has estimated that 
in 2035 more than 300 million adults and children will be obese.6
Obesity is partly regarded as an evolutionary issue. It is postulated that for 
the human population to survive it was necessary to develop a thrifty genotype, 
and genes that facilitate fat reserves for use as energy during harder times were 
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selected.7 The ancestors of humans experienced situations 
that contrasted with the present, which is characterized by 
availability of abundant food and low physical exercise. 
These changes have converted an evolutionary benefit into 
a serious metabolic problem and obesity.
Obesity is associated with increases in morbidity, prema-
ture mortality, impaired quality of life, and large health care 
cost.8–12 The major comorbidities include the following: 
metabolic syndrome, type 2 diabetes, hypertension, dys-
lipidemia, myocardial infarction, and certain cancers.12,13 
Obesity is considered a chronic medical disease state.14–16 
Consequently, more and more strategies focusing on obesity 
treatment are being explored. However, to develop novel 
pharmacological therapies effective against obesity, we must 
understand the main physiological mechanism controlling 
energy homeostasis. Only then will it be possible to ensure 
efficacy, safety, and sustainable weight loss.
Here we review the main physiological mechanisms that 
constitute the cornerstone of pharmacological antiobesity 
strategies. We focus on the most novel and least explored 
areas of research and describe drugs approved or under 
study currently targeting the different systems (Figure 1 
and Table 1).
Regulation of food intake, energy 
balance, and body fat mass
Obesity is defined as abnormal and excessive fat accu-
mulation caused by an imbalance between energy intake 
and caloric expenditure. Body weight control consists of a 
complex mechanism regulated by hormonal, metabolic, and 
nervous pathways. A body weight “set point” existence has 
been suggested for every individual, and it is regulated by 
physiological mechanisms that use energy sensors located 
in the peripheral organs to inform the brain about the energy 
status of the organism. An effective treatment for obesity 
would require an efficient knowledge of factors and mecha-
nisms potentially regulating food intake, energy balance, 
and body fat mass.17
Central regulation of energy homeostasis
The hypothalamus is the central brain structure responsible 
for food intake regulation. Neuronal clusters constitute 
the hypothalamic nuclei interconnecting neuronal circuits 
capable of responding to changes in energy status by modi-
fying the expression of specific neuropeptides, which cause 
changes in energy intake and expenditure. Crucial relevance 
in food intake regulation is exerted by the arcuate nucleus in 
the hypothalamus, where there coexist neurons coexpress-
ing orexigenic peptides such as neuropeptide Y (NPY) and 
agouti-related peptides (AgRP) with an adjacent set of neurons 
coexpressing anorexigenic peptides pro-opiomelanocortin 
(POMC) and cocaine and amphetamine-regulated transcript 
(CART).18 Hypothalamic neurons respond to peripheral 
signals such as leptin, ghrelin, glucose, insulin, and the main 
neurotransmitters by modifying the synthesis of anorexigenic/
orexigenic neuropeptides and finally regulating food intake.
The regulation of food intake and energy expenditure 
at the central nervous system (CNS) involves the action 
of neurotransmitters and neuromodulators. Among the 
neurotransmitters, it was widely described that dopamine 
exhibits relevant effects on food intake. Animal models of 
dopamine deficiency show decreased food intake.19 In fact, 
it has been shown that dopamine activates brain centers of 
reward and pleasure that affect food intake.20 In addition, 
central serotoninergic innervations of the hypothalamus exert 
anorexigenic actions, especially through the receptors 5-hy-
droxytryptamine receptor 2B (5-HT2B) and C (5-HT2C).21 
Signaling by opioid peptides leads the hedonic components 
of food and opioid agonist to induce intake of palatable food. 
In this context, targeting the main central neurotransmitters 
capable of modulating the main hypothalamic neuropetides 
production now constitutes one of the most promising thera-
pies to fight against obesity.
The most recent findings in the field of central regula-
tion of energy homeostasis have revealed that hypothalamic 
lipid metabolism is a crucial mechanism regulating energy 
balance.18 Accordingly, the main peripheral signals that are 
crucial for the regulation of energy balance (leptin, ghre-
lin, and cannabinoids) modulate key enzymes of the lipid 
metabolism such as AMP-activated protein kinase (AMPK) 
and acetil-CoA carboxylase (ACC).22
Another system involved in energy balance regulation at 
the central level is the endocannabinoid system (EC), and, 
specifically, cannabinoid receptor type 1 (CB1) agonism 
has been shown to ensure palatable food consumption. On 
the contrary, the antagonist for CB1 induces weight loss in 
obesity possibly through the improvement of leptin sensitiv-
ity at the central level.23
energy balance regulation by adipose 
tissue
The adipose tissue, classically considered as a lipid reser-
voir, has gained increased attention as an endocrine organ 
involved in energy homeostasis regulation. In addition to 
the fatty acids, the liberation from the adipose tissue of 
bioactive factors named adipokines has been revealed to 
be altered in obesity. Adipokines mediate physiological 
actions contributing to energy homeostasis maintenance 
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Ventromedial Arcuate
AMPK
Amylin
Leptin
Adiponectin
5HTc
POMC/CART
NPY/AgRP
Serotonergic
Gabaergic
Lorcaserin
Rimonabant
Phentermine/topiramate
Pramlintide/metreleptin
LY2405319
Contrave
AdipoRon
Liraglutide
Lipase
GLP-1
Orlistat
Rimonabant
mTOR/pS6K1
CB1
Ghrelin
CCK
Oxyntomodulin
Apolipo IV
Nesfatin-1
DDP-4
Nesfatin-1
Vaspin
PGC1
PPAR
AMPK-SIRT1
FGF-21
BMP-7
Irisin
UCP-1
PRDM16
Lateral
Dopaminergic
CB1
Figure 1 Main targets for the development of drugs to treat obesity.
Notes: in the brain, the dopaminergic, gabaergic, and serotonergic systems constitute the main targets for several antiobesity drugs. At the peripheral level, adipose 
tissue contains several mechanisms susceptible of being modulated in order to control body weight. Brown adipose tissue has emerged as a potential regulator of energy 
expenditure throughout the pharmacological modulation of the adipokines involved in thermogenesis. The gastrointestinal tract constitutes the third target for the treatment 
of obesity currently under study.
Abbreviations: 5-HTc, 5-hydroxytryptamine receptor c; AgRP, agouti-related peptides; AMPK, 5´Adenosine monophosphate-activated protein kinase; BMP-7, Bone 
morphogenetic protein 7; CART, cocaine and amphetamine-regulated transcript; CB1, cannabinoid receptor type i; CCK, cholecystokinin; DDP-4, Dipeptidyl peptidase-4; 
FGF-21, Fibroblast growth factor 21; GLP-1, glucagon-like peptide-1; NPY, neuropeptide Y; PGC1, peroxisome proliferator-activated receptor gamma coactivator; POMC, 
pro-opiomelanocortin; PPAR, peroxisome proliferator-activated receptor; mTOR/S6K1, mammalian target of rapamycin/ribosomal protein S6 kinase beta-1; PRDM16, PR 
domain containing 16; SiRT1, sirtuin 1; UCP-1, uncoupling protein 1.
such as food intake regulation, energy expenditure, and 
insulin sensitivity.24
The isolation of leptin in 1999 represents an important 
starting point in the study of the adipose tissue as an endocrine 
organ. Leptin is produced mainly in the white adipose tissue 
(WAT) and circulates in plasma correlating with the fat con-
tent. It acts through the leptin receptors in the arcuate nucleus 
of the hypothalamus regulating appetite. At the hypothalamic 
level, the mechanism of leptin action involves the inhibition 
of orexigenic neuropeptides in parallel with the increase in 
anorexigenic peptides.25 In addition to leptin, an increasing 
number of novel adipokines were identified, some of whose 
functions still remain unknown. Among the adipokines, the 
adiponectin has attracted considerable attention because of 
its insulin-sensitizing properties.26 It has been found that 
adiponectin levels are downregulated under adverse fat dis-
tribution and associated with adipose tissue dysfunction.26
Dipeptidyl peptidase-4 (DPP-4) has been recently iden-
tified as an adipokine that shows an elevated production 
from adipose tissue in obese patients when compared with 
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lean controls.27 Several studies support the relationship 
among elevated DPP-4 release and obesity and insulin 
resistance.28 Another signal identified as an adipokine is 
nesfatin-1, which is secreted from different tissues such as 
brain, stomach, and adipose tissue. Several studies focusing 
on the mechanism of action of nesfatin-1 have proposed it 
as a novel satiety molecule with a direct effect on glucose 
metabolism.29 Vaspin has also emerged as an adipokine with 
the potential to improve insulin resistance, although the exact 
mechanism of action is still not elucidated.30
Two types of adipose tissue have been described: WAT, 
which stores fat, and brown adipose tissue (BAT), which 
dissipates energy in the form of heat through nonshiver-
ing thermogenesis. The adipokines produced by BAT 
have proved to be capable of exerting beneficial effects 
on metabolism. The capacity of the BAT-derived adipok-
ines include differentiation of adipose stem cells into brite 
adipocytes, which induce thermogenic activation, increase 
energy expenditure and finally, reduce fat composition 
and body wight. The adipokines derived from BAT are the 
subject of a wide range of studies. Among them, fibroblast 
growth factor 21 (FGF-21) was discovered as an important 
metabolic regulator primarily produced by the liver and 
adipose tissue.31 FGF-21 exerts significant glucose- and 
lipid-lowering actions and has thermogenic effects. The 
administration of FGF-21 produced beneficial metabolic 
effects in animal models.31 The mechanism of action for the 
metabolic effects of FGF-21 is associated with its ability to 
activate peroxisome proliferator-activated receptor gamma 
coactivator 1-alpha (PGC1-α), which is a master regulator 
of mitochondrial biogenesis and oxidative metabolism.32 In 
addition, there is a positive role for FGF-21 in regulating the 
interaction between AMPK and sirtuin 1 (SIRT1), which is 
essential for brown thermogenesis.33
Bone morphogenetic protein 7 (BMP-7) induces brown 
adipogenesis in subcutaneous adipose tissue, increases 
energy expenditure, reduces food intake, and decreases 
weight gain.34,35 These effects might be mediated by its capac-
ity to induce the activation of the p18-AMPK pathway that 
regulates the expression of thermogenic factors such as PR 
domain containing 16 (PRDM16), PGC1-α, and uncoupling 
protein 1 (UCP-1).
Irisin was recently described as a myokine and an adi-
pokine produced by cleavage of the fibronectin type 3 domain 
containing 5 (FNDC5) protein.36,37 It has been proposed as 
a regulator of peroxisome proliferator-activated receptor 
gamma (PPARγ) and is attributed to browning properties 
such as increases of brown fat, UCP-1 levels, and oxygen 
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consumption. Several studies have reported an increase in irisin 
production after exercise. However, recent studies in humans 
indicate that neither acute nor chronic exercise increases the 
endogenous concentration of FNDC5/irisin.38,39
energy balance regulation  
by gastrointestinal tract
More than 30 peptides are secreted from the enteroendocrine 
cells of the gastrointestinal tract in response to ingested food. 
These peptides are involved in hunger/satiety perception 
by interacting with long-acting hormones involved in body 
weight regulation such as leptin and insulin to maintain 
energy homeostasis.40 The majority of satiation-inducing 
gut peptides mediate their effects via vagal afferent fibers, 
although some enter the brain from the circulation and exert 
their effects directly.41 In addition, there is a fundamental role 
for these hormones in several digestive functions, including 
gastric emptying and energy intake regulation.42 Thus, the 
gastrointestinal tract-derived peptides involved in the con-
trol of energy homeostasis have recently garnered a notable 
degree of attention. Among these peptides, the most studied 
include cholecystokinin (CCK), glucagon-like peptide-1 
(GLP-1), oxyntomodulin, peptide YY (PYY), apolipoprotein 
A.IV, and enterostatin.43 Since its isolation in 1999, ghrelin 
has been considered the most relevant hormone because it is 
the only stomach-derived peptide with orexigenic actions.44,45 
Another gastrointestinal hormone, GLP-1, is postprandi-
ally released primarily from the distal small intestine and 
colon L cells.44 In humans, GLP-1 reduces energy intake, 
gastric emptying rates, and energy consumption.46 It has 
been suggested that there is an antagonistic effect of ghrelin 
on GLP-1 in the regulation of food intake.43 In addition, an 
inverse relationship between circulating levels of ghrelin 
and GLP-1 has been described.46 This result may indicate 
an interaction between these two peptides. Nesfatin-1 is a 
stomach-derived peptide involved in food intake regulation 
that was recently discovered, and it is receiving increasing 
interest as a regulator of energy homeostasis.47
The EC system, and particularly CB1, has emerged as 
a relevant target to treat obesity and its pathologies. It is 
known that EC production is regulated by nutritional status 
at specific areas of the brain involved in modulating feeding 
behavior. However, the EC system is not only present at the 
central level. It was shown that the major peripheral organs 
involved in metabolism regulation such as adipose tissue, the 
liver, the endocrine pancreas, and the skeletal muscles are 
targets for cannabinoid actions.48 The EC system plays a role 
in glucose homeostasis, lipogenesis, and insulin sensitivity 
regulation in the periphery.48 Moreover, it was recently 
demonstrated that CB1 receptors are localized in the stomach 
in the neuroendocrine gastric cells producing ghrelin.49 All 
of the recent studies regarding the involvement of the gastric 
EC system suggest that any regulator mechanism at this level 
can be implicated in gastric–brain communication and the 
mediation of energy balance control.
Recent studies of the metabolic control of energy bal-
ance focused on the intracellular pathway mammalian target 
of rapamycin/ribosomal protein S6 kinase beta-1 (mTOR/
S6K1), which has been proposed as an intracellular energy 
sensor. This system is regulated by nutritional status and 
pathological situations such as obesity and diabetes in the 
brain and several peripheral tissues such as the liver and 
skeletal muscle.50
This intracellular pathway participates in the brain– 
stomach connection and regulation of energy balance indi-
rectly through the action of gastric peptides on hypothalamic 
neurons, which regulates food intake. Recently, a novel 
gastric mechanism regulating central food intake was 
described involving a connection between gastric can-
nabinoid receptor CB1 and ghrelin through the intracellular 
mTOR pathway via the neural control of the vagus nerve.51 
The work showed that the pharmacological blockade of 
the cannabinoid receptor in fasting states by the use of two 
antagonists (rimonabant and AM281) is sensed by the gastric 
cells as a satiety signal comparable to food intake. This signal 
consequently decreases ghrelin secretion from the stomach 
and decreases food intake and body weight.
Future studies focusing on this novel mechanism will 
reveal whether additional gastrokines besides ghrelin might 
be involved in this gastric system to regulate food intake by 
the EC system and via mTOR. Previous studies have indi-
cated that the production of the adipokine nesfatin-1 opposes 
the effects of ghrelin and it is also regulated by the gastric 
intracellular mTOR pathway.52
The classical idea of a central regulation of food intake and 
body weight has led to the concept that energy balance results 
from the interaction between the CNS and peripheral organs 
directly involved in body weight regulation such as the gas-
trointestinal tract and adipose tissue. Novel therapeutic strate-
gies are being designed to treat obesity by acting on the main 
pathways communicating with the brain and periphery.
New pharmacological management 
interventions for obesity
The strategies recommended for weight loss include lifestyle 
interventions, pharmacotherapy, and bariatric surgery.14 
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The foundation of obesity care consists in lifestyle changes 
that include diet, physical activity, and behavior change 
therapies. The most important strategy for sustainable body 
weight loss is caloric intake reduction together with increased 
and maintained physical activity.53,54
With the exception of bariatric surgery, individual phar-
macological interventions have shown limited success.41,55,56 
An effective pharmacological intervention to treat obesity 
should provide sustained weight loss and avoid adverse 
effects. However, it is difficult to achieve this goal because 
energy balance regulation has redundancy and overlapping 
physiological functions. Thus, weight loss is affected by 
external factors that limit the effectiveness of pharmacologi-
cal interventions.
The antiobesity drugs currently under investigation act 
mainly at two different levels. The first level is the central 
level, and the second level is the peripheral organs with 
relevant roles in energy homeostasis such as adipose tissue 
and the gastrointestinal tract.
Pharmacotherapy is approved for patients with a body 
mass index (BMI) $30 kg/m2 or $27 kg/m2 when compli-
cated by obesity-related comorbidity (FDA: Food and Drug 
Administration).14
The brain as a target for the 
development of antiobesity drugs
The role of the brain in appetite regulation and body weight 
control is well known.57 Thus, drugs targeting the CNS might 
represent the most promising obesity therapy.
The drugs acting through the CNS affect neurotransmit-
ters with anorexiants or appetite suppressant actions. These 
treatments have targeted three monoamine receptor systems 
in the hypothalamus, namely, the noradrenergic, dopamin-
ergic, and serotonergic systems.58 The first compound 
introduced as an appetite suppressant was amphetamine, 
which was addictive and had euphoric side effects. To reduce 
these side effects, amphetamine-derived anorexiants such as 
phentermine were produced, and this is the most commonly 
prescribed agent in the USA but is prohibited in Europe. 
The most common side effects of the anorexiant compounds 
are restlessness, insomnia, dry mouth, constipation, and 
increased blood pressure and heart rate. The phentermine/
topiramate combination contains a stimulator of noradrena-
line, dopamine, and serotonin release with an anticonvulsant 
drug. This combination treatment was approved by FDA 
because present synergic effects allow the use of lower doses 
of each substance and reduced the toxicity. The mechanism 
responsible for weight loss is uncertain, but it is thought to 
be mediated through its modulation of gamma aminobutyric 
acid receptors, inhibition of carbonic anhydrase, and antago-
nism of glutamate to reduce food intake.14 Clinical trials have 
shown the efficacy and safety of the treatment. The major 
concern about this medication is teratogenicity, and hence it 
should never be administered to pregnant women.
Specific central serotonin receptor agonism represents 
an effective pharmacological approach to body weight loss. 
The first drugs developed to target serotonin receptors were 
fenfluramine and dexfenfluramine. They were used in combi-
nation with phentermine. However, the drugs were withdrawn 
because of adverse cardiovascular and lung effects. These 
adverse effects were produced by its 5-HT2B agonism, which 
is expressed in the cardiovascular system. Novel and safe 
strategies are necessary to develop drugs acting specifically in 
another family member of the 5-HT such as 5-HT2C. This fam-
ily member is only expressed in the brain and participates in 
energy balance regulation. One appetite suppressant approved 
by the FDA in 2012 was lorcaserin, which is a selective 5-HT
2C
 
receptor agonist that is thought to decrease food intake through 
the POMC system of neurons.59
Another drug that suppresses appetite and weight gain is 
rimonabant. It is a CB1 antagonist/inverse agonist developed 
in the mid-1990s. This drug was licensed in Europe as an 
antiobesity agent in 2006. However, it was never approved 
in the US. The presence of serious psychiatric problems led 
to its suspension in 2008. This decision rapidly led to the 
termination of several CB1-receptor-antagonist antiobesity 
drug development programs.60
In September 2014, the FDA has approved two new drugs 
for obesity. One of them is Contrave, a CNS-level-acting drug 
that is a combination of naloxone and bupropion formulated 
for extended release. Naloxone is a nonselective antagonist 
for opioids, and bupropion a norepinephrine and dopamine 
reuptake inhibitor.61 The second approved drug is liraglutide 
3 mg, an agonist of GLP-1 receptor acting at the central and 
peripheral levels. All these drugs must be used as adjuncts 
to diet and exercise.
Adipose tissue as a target  
to treat obesity
Obesity is characterized by excessive fat accumulation pre-
dominantly in visceral depots, and it is associated with the 
development of several pathologies such as cardiovascular 
diseases, type 2 diabetes, and fatty liver disease.62
The main well-known adipokines are deregulated in obe-
sity, and they are involved in the regulation of energy balance 
through their role in food intake control, fat distribution, 
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insulin sensitivity, and energy expenditure.24 Adipokines 
have emerged as potential biomarkers and pharmacological 
treatment strategies for obesity. A number of adipokines 
are currently being studied as potential candidates for the 
development of antiobesity therapies. Such adipokines 
include leptin, adiponectin, DPP-4, FGF-21, nesfatin-1, 
BMP-7, tumor necrosis factor alpha (TNF-α), apelin, and 
vaspin.62 The majority of these adipokines act in the brain 
to increase energy expenditure and cause weight loss.63,64 
Thus, the concept of an interconnection between the CNS 
and adipose tissue has promoted the search for novel adi-
pokines that affect obesity and may be potential targets for 
pharmacological strategies.
Among the known adipokines, only leptin has reached 
advanced clinical study phases, and the remaining adipok-
ines are currently under preclinical studies. Leptin secretion 
from adipose tissue was discovered in 1994, and it was pro-
posed as an obesity treatment on the basis of its anorexigenic 
effect. Leptin acts on the hypothalamic nucleus, which regu-
lates body weight and appetite.25 However, obese patients pres-
ent elevated serum levels of this adipokine, and there is central 
resistance to the weight-lowering effects of exogenously 
administered leptin.65,66 Thus, recombinant leptin is not used 
for clinical treatment, but only in a small number of centers as 
a protocol for research in patients with congenital leptin defi-
ciency.67 Metreleptin is an analog of human leptin that has been 
recently approved for the treatment of lipodystrophy in Japan. 
However, it has not yet been approved by the US and Euro-
pean regulatory agencies.68 Recently, leptin was combined 
with other peptides such as amylin, exendin-4, and FGF-21 as 
promising antiobesity drugs.69 However, the last clinical study, 
based on the administration of a combination of the amylin 
agonist and leptin analogs (pramlintide/metreleptin), showed 
efficacy in reducing body weight. However, this trial was sus-
pended because of relevant adverse effects. Future antiobesity 
strategies investigating leptin analogs in diet-induced obese 
rodents and human obesity will require increased potency 
and sustained action to obtain sustainable weight loss, ensure 
safety, and minimize adverse effects.
Adiponectin is another adipokine proposed as a prom-
ising therapy for obesity, in view of its peripheral and 
central effects on improving insulin sensitivity, lowering 
body weight, and increasing energy expenditure.26 Several 
studies have been conducted with recombinant adiponectin 
and adiponectin analogs. These studies showed beneficial 
effects on insulin sensitivity and body weight.26,70,71 Recent 
research suggests a more promising strategy includes the 
development of adiponectin receptor agonists, as shown by 
the initial studies with AdipoRon. AdipoRon was shown to 
have beneficial effects on insulin resistance in mice receiving 
a high-fat diet.72 However, the main limitation of this therapy 
is the lack of clinical trial data in humans.
An additional adipokine that has recently attracted special 
interest is DPP-4, which was initially studied as an incretin 
inhibitor. Several DPP-4 antagonists are clinically used as 
antidiabetic drugs.73 However, a new pathway has been iden-
tified by specifically targeting actions of DPP-4 directly at 
the adipose tissue. The effects of DPP-4 on metabolism were 
produced independently of their actions mediated by incretins. 
The main limitation of this therapeutic strategy is that human 
data on DPP-4 action as an adipokine are not available.
Other candidate adipokines were examined in the search 
for therapeutic targets able to provide a stable and sustained 
weight loss. These candidates must be accompanied by 
an improvement of the obesity-associated pathologies. 
 Examples of candidate adipokines include nesfatin-1, vaspin, 
and amylin. However, the main limitation to advancements 
in the development of these candidates is the lack of human 
data. In addition, the mechanisms of action controlling effects 
in regulating homeostasis have not been identified.
Harnessing the thermogenic effects  
of new adipokines is a novel strategy  
to treat obesity
A new trend has recently emerged in treating obesity by tar-
geting energy expenditure. The novel strategies are focused 
on the findings that human BAT, which dissipates energy by 
increased energy expenditure, is inversely correlated with 
BMI.74 The adipokines produced by BAT have beneficial 
effects on metabolism and browning action on WAT that 
reduces fat composition and body weight.
LY2405319 is an FGF-21 analog that has been produced 
and tested in a proof-of-concept trial. The trial reported ben-
eficial effects on body weight reduction and fasting insulin. 
It also improved dyslipidemia in subjects with obesity and 
type 2 diabetes.33 Therefore, FGF-21-based therapies might be 
effective for the treatment of obesity and related disorders.
BMP-7 has been suggested as a novel therapeutic 
approach for obesity and metabolic diseases. However, there 
are no clinical data available on the effects of this adipokine 
in obesity and metabolic diseases.
Despite the initial expectation of using irisin as an 
antiobesity drug, the in vivo and in vitro data obtained in 
rodents has not been reproduced in humans. This lack of data 
suggests that we should be careful when using pharmacologi-
cal applications of irisin to induce browning.
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There are currently no adipokines approved for weight 
loss, and only an analog of amylin is in phase I study. The 
drug is a combination of leptin and an amylin analog (pram-
lintide, metreleptin). The drug was moved to a phase II study 
but had to be interrupted owing to the generation of antibodies 
and severe adverse effects.
In summary, the novel strategies to treat obesity by target-
ing adipose tissue have not been completely addressed. The 
main limitation of the drugs targeting adipokines is the lack 
of knowledge regarding the exact mechanisms in controlling 
obesity. The major problem in the development of drugs 
targeting browning and thermogenesis is a safety issue. The 
main risk is that thermogenesis activation involves adrenergic 
activity and might induce cardiovascular effects. In the future 
it will be important to produce thermogenic analogs with 
mechanisms independent of adrenergic activation.
Current and future strategies 
targeting the gastrointestinal tract 
in obesity treatment
Gastric surgery is the most effective treatment for obesity 
and has led to the investigation of signals derived from the 
gastrointestinal tract as promising targets in treating obesity. 
Recent antiobesity research has been focused on peripheral 
hunger and satiety signals that require central integration to 
communicate the organism’s nutritional status to the brain 
centers and allow efficient energy homeostasis.75
The gastrointestinal tract and the gastrokines together 
with novel systems such as the EC system and the intracel-
lular mTOR pathway represent promising pharmacological 
targets for the development of therapies against obesity.
Orlistat is currently the only approved drug that acts at 
the gastrointestinal level. It is a potent lipase inhibitor that 
reduces intestinal fat absorption and is recommended for 
long-term obesity treatment. The safety of this drug is based 
on data showing fat is not absorbed and consequently does 
not display nondesirable systemic effects. However, the main 
limitation of orlistat is gastrointestinal symptoms that, in 
general, can be avoided by patients if they limit their high-
fat diet. Another limitation is that in addition to reducing fat 
absorption, the drug also inhibits vitamins. However, this 
problem can be solved with vitamin supplementation.76
Another novel therapy based on gut–brain communication 
takes advantage of the development of GLP-1 analogs such 
as liraglutide, which is an agonist for the GLP-1 receptor. 
This drug was previously used for diabetes treatment. A new 
strategy currently being explored is the use of liraglutide at 
higher doses than those used for diabetes. The objective is to 
induce weight loss and reduce obesity. In addition, the rate of 
liraglutide metabolism is much lower than for GLP-1, which 
ensures a longer duration of action. Occasionally, liraglutide 
treatment can induce gastrointestinal effects such as nausea 
and vomiting.61 As mentioned above, the use of liraglutide 
3 mg for obesity treatment was very recently approved 
(September 2014).
One very promising strategy to treat obesity is the 
modulation of the EC system, but this was scuttled with the 
withdrawal of rimonabant due to adverse CNS-related side 
effects. However, the peripheral antagonist of CB1 receptors 
might still represent a new possibility with beneficial meta-
bolic effects for cannabinoid-derived drugs. Drugs that act 
on the periphery rather than on the CNS should be explored 
in the future. However, a predictable limitation of this type 
of therapy is the short half-life characteristics of drugs at the 
gastric level, which complicates their oral administration. In 
addition, the use of drugs acting on a single molecular target 
provides only modest reductions in body weight.
Incretins or other pharmacological agents may play an 
important role in combating the obesity epidemic. Although 
any antiobesity drug may affect one or several of the systems 
that control food intake and energy expenditure, it is unlikely 
that a single pharmacological agent will be an effective 
obesity treatment. Thus, future strategies to treat obesity will 
have to induce effective weight loss and will likely require 
the coadministration of medications that act through differ-
ent mechanisms.
Therapeutic weight loss interventions have provided only 
limited long-term success. An effective obesity treatment 
would require an evaluation of factors potentially affecting 
energy intake, expenditure, and metabolism.17 Because the 
factors causing obesity are incompletely understood, weight 
loss strategies may not address the root causes of energy 
imbalance.17,77 Therefore, there is an urgent need to develop 
novel pharmacological treatment strategies targeting the 
mechanisms underlying positive energy balance and exces-
sive and adverse fat accumulation. One key priority at present 
is to delineate how mechanisms governing food intake and 
body fat content are altered in an obesogenic environment. 
This information will allow the development of effective new 
obesity prevention and treatment strategies.
The reduction of body weight might not be the only or 
best approach to improve obesity-related diseases. Novel 
treatment concepts may include changing metabolically 
unhealthy patients into metabolically healthy obese indi-
viduals. Such a phenotype switch could be achieved by 
a reduction in fat mass, improvement of adipose tissue 
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function, or normalization of the adipokine, diabetogenic, 
and proinflammatory profiles.62
Conclusion
In conclusion, owing to the limited efficacy of dietary 
restrictions, physical exercise, and lifestyle modifications 
in controlling obesity, the only realistic approach available 
to clinicians is pharmacotherapy. The drugs currently in use 
all lead to an approximately 5 kg weight loss compared with 
placebo, and no striking differences are observed. A better 
understanding of the mechanisms controlling appetite, sati-
ety, and energy homeostasis may allow the development of 
more effective drugs in the future.
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